Geographic Atrophy Market Report 2025–2035
Description
The Geographic Atrophy Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Geographic atrophy (GA) is closely linked with ageing, predominantly affecting people aged 60 and above. As a result, population ageing stands out as one of the strongest drivers of future demand. A 2024 Journal of the American Medical Association (JAMA) study projects that global cases of age-related macular degeneration will rise from 196 million today to 288 million by 2040.
As prevalence rises, the need for effective therapies is intensifying. Biopharmaceutical companies are responding by advancing treatments designed with greater durability, improved safety, and enhanced usability for elderly patients. Uptake of recently approved drugs such as pegcetacoplan and avacincaptad pegol has already been strong across high-income regions, where ageing populations are expanding fastest. Beyond clinical impact, the demographic shift also represents a commercial imperative: drug makers must adapt by designing accessible therapies and building patient support programmes to serve a growing, vulnerable population segment.
The therapeutic impact of currently approved complement inhibitors for geographic atrophy (GA) remains the subject of ongoing debate. While these drugs have demonstrated the ability to slow lesion growth, the effect is modest and does not consistently translate into meaningful improvements in functional vision. Results from the pivotal OAKS and DERBY Phase 3 trials showed average reductions in GA lesion enlargement of around 16–22% over one to two years, with clearer separation from sham groups emerging over time. However, improvements in key functional outcomes, such as best-corrected visual acuity, were not reliably achieved.
Safety concerns further complicate adoption. Post-marketing surveillance and registry data have reported clusters of intraocular inflammation and other retinal inflammatory events in treated patients, prompting tighter monitoring requirements and more selective patient eligibility. Coupled with the ongoing burden of frequent intravitreal injections, these factors have dampened enthusiasm for broad use.
In practice, current therapies provide meaningful yet limited benefits, with uptake largely confined to carefully chosen patient populations. For the wider retinal community, stronger long-term data on safety and functional outcomes remain essential before these treatments can achieve mainstream adoption.
U.S. trade tariffs have the potential to indirectly influence the global market for geographic atrophy (GA) therapies by raising production costs for treatments and their delivery devices. While finished biopharmaceuticals such as GA drugs are often exempt from high tariffs due to their medical necessity, the upstream components essential to their manufacture–such as sterile fill–finish equipment, specialised glass vials, and injection devices–are frequently sourced from tariff-affected countries. Any increase in costs for these inputs drives up overall production expenses, which can, in turn, translate into higher treatment prices. Given that GA therapies already carry premium price points, even marginal cost increases risk complicating payer negotiations, restricting patient access, and slowing adoption in cost-sensitive healthcare systems.
The implications extend well beyond the U.S. Pharmaceutical companies typically operate integrated supply chains spanning multiple regions, and while large multinationals with diversified sourcing can absorb or offset tariff risks, smaller biotech firms dependent on single-source suppliers may face significant margin pressures. For these companies, partnerships with larger players may become a necessity. Over time, persistent tariffs could prompt more investment in localised manufacturing and supplier diversification, reshaping competitive dynamics and altering how quickly GA therapies can scale globally.
In response, companies may fast-track investments in domestic production sites or shift parts of their supply chains to tariff-neutral regions to mitigate exposure. This restructuring could elevate the role of emerging markets such as Asia Pacific and Latin America as alternative manufacturing hubs. However, such transitions demand considerable capital and time, potentially slowing innovation or delaying the availability of new therapies in the short term. In the longer run, the interaction between tariffs, localisation, and global demand is likely to redefine how GA treatments are priced, distributed, and adopted worldwide.
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 19 leading national markets:
The report also includes profiles and for some of the leading companies in the Geographic Atrophy Market, 2025 to 2035, with a focus on this segment of these companies' operations.
Overall world revenue for Geographic Atrophy Market, 2025 to 2035 in terms of value the market will surpass US$7,400.0 million in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
In summary, our 320+ page report provides you with the following knowledge:
Find quantitative and qualitative analysis with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
Growing Prevalence of Geographic Atrophy
Geographic atrophy (GA) is closely linked with ageing, predominantly affecting people aged 60 and above. As a result, population ageing stands out as one of the strongest drivers of future demand. A 2024 Journal of the American Medical Association (JAMA) study projects that global cases of age-related macular degeneration will rise from 196 million today to 288 million by 2040.
As prevalence rises, the need for effective therapies is intensifying. Biopharmaceutical companies are responding by advancing treatments designed with greater durability, improved safety, and enhanced usability for elderly patients. Uptake of recently approved drugs such as pegcetacoplan and avacincaptad pegol has already been strong across high-income regions, where ageing populations are expanding fastest. Beyond clinical impact, the demographic shift also represents a commercial imperative: drug makers must adapt by designing accessible therapies and building patient support programmes to serve a growing, vulnerable population segment.
Limited Efficacy of Current Therapies is Hindering the Market Growth
The therapeutic impact of currently approved complement inhibitors for geographic atrophy (GA) remains the subject of ongoing debate. While these drugs have demonstrated the ability to slow lesion growth, the effect is modest and does not consistently translate into meaningful improvements in functional vision. Results from the pivotal OAKS and DERBY Phase 3 trials showed average reductions in GA lesion enlargement of around 16–22% over one to two years, with clearer separation from sham groups emerging over time. However, improvements in key functional outcomes, such as best-corrected visual acuity, were not reliably achieved.
Safety concerns further complicate adoption. Post-marketing surveillance and registry data have reported clusters of intraocular inflammation and other retinal inflammatory events in treated patients, prompting tighter monitoring requirements and more selective patient eligibility. Coupled with the ongoing burden of frequent intravitreal injections, these factors have dampened enthusiasm for broad use.
In practice, current therapies provide meaningful yet limited benefits, with uptake largely confined to carefully chosen patient populations. For the wider retinal community, stronger long-term data on safety and functional outcomes remain essential before these treatments can achieve mainstream adoption.
What would be the Impact of US Trade Tariffs on the Global Geographic Atrophy Market ?
U.S. trade tariffs have the potential to indirectly influence the global market for geographic atrophy (GA) therapies by raising production costs for treatments and their delivery devices. While finished biopharmaceuticals such as GA drugs are often exempt from high tariffs due to their medical necessity, the upstream components essential to their manufacture–such as sterile fill–finish equipment, specialised glass vials, and injection devices–are frequently sourced from tariff-affected countries. Any increase in costs for these inputs drives up overall production expenses, which can, in turn, translate into higher treatment prices. Given that GA therapies already carry premium price points, even marginal cost increases risk complicating payer negotiations, restricting patient access, and slowing adoption in cost-sensitive healthcare systems.
The implications extend well beyond the U.S. Pharmaceutical companies typically operate integrated supply chains spanning multiple regions, and while large multinationals with diversified sourcing can absorb or offset tariff risks, smaller biotech firms dependent on single-source suppliers may face significant margin pressures. For these companies, partnerships with larger players may become a necessity. Over time, persistent tariffs could prompt more investment in localised manufacturing and supplier diversification, reshaping competitive dynamics and altering how quickly GA therapies can scale globally.
In response, companies may fast-track investments in domestic production sites or shift parts of their supply chains to tariff-neutral regions to mitigate exposure. This restructuring could elevate the role of emerging markets such as Asia Pacific and Latin America as alternative manufacturing hubs. However, such transitions demand considerable capital and time, potentially slowing innovation or delaying the availability of new therapies in the short term. In the longer run, the interaction between tariffs, localisation, and global demand is likely to redefine how GA treatments are priced, distributed, and adopted worldwide.
What Questions Should You Ask before Buying a Market Research Report?
- How is the geographic atrophy market evolving?
- What is driving and restraining the geographic atrophy market?
- How will each geographic atrophy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
- How will the market shares for each geographic atrophy submarket develop from 2025 to 2035?
- What will be the main driver for the overall market from 2025 to 2035?
- Will leading geographic atrophy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
- Who are the leading players and what are their prospects over the forecast period?
- What are the geographic atrophy projects for these leading companies?
- How will the industry evolve during the period between 2025 and 2035? What are the implications of geographic atrophy projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the geographic atrophy market?
- Where is the geographic atrophy market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the geographic atrophy market today, and over the next 10 years:
- Our 323-page report provides 130 tables and 190 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2035 and other analysis reveal commercial prospects
- In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
- You will find original analysis, with business outlooks and developments.
- Discover qualitative analysis (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising geographic atrophy prices and recent developments.
Segments Covered in the Report
Type
- Focal GA
- Multifocal GA
- Confluent GA
Drugs
- Pegcetacoplan (SYFOVRE)
- Avacincaptad pegol (IZERVAY)
- Tinlarebant (LBS-008)
- Gildeuretinol (ALK-001)
- Others
Route of Administration
- Intravitreal Route
- Intravenous Route
- Others
Age Group
- Below 60 Years
- Above 60 Years
- Above 70 Years
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 19 leading national markets:
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Denmark
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
The report also includes profiles and for some of the leading companies in the Geographic Atrophy Market, 2025 to 2035, with a focus on this segment of these companies' operations.
Leading companies profiled in the report
- Alkeus Pharmaceuticals, Inc.
- Annexon, Inc.
- Apellis Pharmaceuticals
- Astellas Pharma Inc.
- AstraZeneca
- Aviceda Therapeutics
- Bausch + Lomb
- Belite Bio‚Ñ¢ Inc.
- Boehringer Ingelheim International GmbH
- Cognition Therapeutics
- F. Hoffmann-La Roche Ltd.
- Ionis Pharmaceuticals
- Johnson & Johnson
- Santen Pharmaceutical Co., Ltd.
- Stealth BioTherapeutics
Overall world revenue for Geographic Atrophy Market, 2025 to 2035 in terms of value the market will surpass US$7,400.0 million in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Geographic Atrophy Market, 2025 to 2035 report help you?
In summary, our 320+ page report provides you with the following knowledge:
- Revenue forecasts to 2035 for Geographic Atrophy Market, 2025 to 2035, with forecasts for type, drugs, route of administration, age group, and distribution channel, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2035 for five regional and 19 key national markets - See forecasts for the Geographic Atrophy Market, 2025 to 2035 in North America, Europe, Asia Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Geographic Atrophy Market, 2025 to 2035.
Find quantitative and qualitative analysis with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
Table of Contents
323 Pages
- 1 Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Geographic Atrophy Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report Include:
- 1.6 Who is This Report For?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Visiongain Reports
- 1.10 About Visiongain
- 2 Executive Summary
- 3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.3 Impact Analysis
- 3.3.1 Market Driving Factors
- 3.3.1.1 Expanding Clinical Trial Pipeline for GA Treatments
- 3.3.1.2 Rising Ageing Population Worldwide is Driving the Demand for GA Drugs
- 3.3.1.3 Growing Prevalence of Geographic Atrophy
- 3.3.1.4 Approval of Novel and Advanced Drugs
- 3.3.2 Market Restraining Factors
- 3.3.2.1 High Treatment Costs
- 3.3.2.2 Limited Efficacy of Current Therapies
- 3.3.2.3 Regulatory and Reimbursement Hurdles Across Regions
- 3.3.2.4 Low Awareness in Emerging and Low-income Markets
- 3.3.3 Market Opportunities
- 3.3.3.1 Development of Oral and Less Invasive Therapies
- 3.3.3.2 Growth Potential in Emerging Markets including Asia Pacific and Latin America
- 3.3.3.3 Strategic M&A and Partnerships Among Market Players for Faster Innovation and Expansion
- 3.4 U.S. Tariffs: What's the Impact on Global Geographic Atrophy Market?
- 3.4.1 Overview
- 3.4.2 V-Shaped Recovery Scenario
- 3.4.2.1 Why V-Shaped Recovery?
- 3.4.2.2 Impact from Tariffs
- 3.4.2.3 Market Dynamics and Demand Recovery
- 3.4.2.4 Policy and Funding Support
- 3.4.2.5 Timeframe for Recovery
- 3.4.3 U-Shaped Recovery Scenario
- 3.4.3.1 Why U-Shaped Recovery?
- 3.4.3.2 Impact from Tariffs
- 3.4.3.3 Market Dynamics and Demand Recovery
- 3.4.3.4 Policy and Funding Support
- 3.4.3.5 Timeframe for Recovery
- 3.4.4 L Shaped Recovery Scenario
- 3.4.4.1 Why L-Shaped Recovery?
- 3.4.4.2 Impact from Tariffs
- 3.4.4.3 Market Dynamics and Demand Recovery
- 3.4.4.4 Policy and Funding Support
- 3.4.4.5 Timeframe for Recovery
- 3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2025-2030) and Long-term (2025-2035) Planning?
- 3.4.6 Impact of U.S. and China Trade War on Geographic Atrophy Market
- 3.5 Regulatory Framework
- 3.6 Emerging Markets and Megatrends
- 3.7 Porter's Five Forces Analysis
- 3.7.1 Bargaining Power of Suppliers
- 3.7.2 Bargaining Power of Buyers
- 3.7.3 Competitive Rivalry
- 3.7.4 Threat of Substitutes
- 3.7.5 Threat of New Entrants
- 3.8 PEST Analysis
- 4 Geographic Atrophy Market Analysis by Type
- 4.1 Key Findings
- 4.2 Type Segment: Market Attractiveness Index
- 4.3 Geographic Atrophy Market Size Estimation and Forecast by Type
- 4.4 Focal GA
- 4.4.1 Market Size by Region, 2025-2035 (US$ Million)
- 4.4.2 Market Share by Region, 2025 & 2035 (%)
- 4.5 Multifocal GA
- 4.5.1 Market Size by Region, 2025-2035 (US$ Million)
- 4.5.2 Market Share by Region, 2025 & 2035 (%)
- 4.6 Confluent GA
- 4.6.1 Market Size by Region, 2025-2035 (US$ Million)
- 4.6.2 Market Share by Region, 2025 & 2035 (%)
- 5 Geographic Atrophy Market Analysis by Drugs
- 5.1 Key Findings
- 5.2 Drugs Segment: Market Attractiveness Index
- 5.3 Geographic Atrophy Market Size Estimation and Forecast by Drugs
- 5.4 Pegcetacoplan (SYFOVRE)
- 5.4.1 Market Size by Region, 2025-2035 (US$ Million)
- 5.4.2 Market Share by Region, 2025 & 2035 (%)
- 5.5 Avacincaptad pegol (IZERVAY)
- 5.5.1 Market Size by Region, 2025-2035 (US$ Million)
- 5.5.2 Market Share by Region, 2025 & 2035 (%)
- 5.6 Tinlarebant (LBS-008)
- 5.6.1 Market Size by Region, 2025-2035 (US$ Million)
- 5.6.2 Market Share by Region, 2025 & 2035 (%)
- 5.7 Gildeuretinol (ALK-001)
- 5.7.1 Market Size by Region, 2025-2035 (US$ Million)
- 5.7.2 Market Share by Region, 2025 & 2035 (%)
- 5.8 Others
- 5.8.1 Market Size by Region, 2025-2035 (US$ Million)
- 5.8.2 Market Share by Region, 2025 & 2035 (%)
- 6 Geographic Atrophy Market Analysis by Route of Administration
- 6.1 Key Findings
- 6.2 Route of Administration Segment: Market Attractiveness Index
- 6.3 Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
- 6.4 Intravitreal Route
- 6.4.1 Market Size by Region, 2025-2035 (US$ Million)
- 6.4.2 Market Share by Region, 2025 & 2035 (%)
- 6.5 Intravenous Route
- 6.5.1 Market Size by Region, 2025-2035 (US$ Million)
- 6.5.2 Market Share by Region, 2025 & 2035 (%)
- 6.6 Others
- 6.6.1 Market Size by Region, 2025-2035 (US$ Million)
- 6.6.2 Market Share by Region, 2025 & 2035 (%)
- 7 Geographic Atrophy Market Analysis by Distribution Channel
- 7.1 Key Findings
- 7.2 Distribution Channel Segment: Market Attractiveness Index
- 7.3 Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
- 7.4 Hospital Pharmacies
- 7.4.1 Market Size by Region, 2025-2035 (US$ Million)
- 7.4.2 Market Share by Region, 2025 & 2035 (%)
- 7.5 Retail Pharmacies
- 7.5.1 Market Size by Region, 2025-2035 (US$ Million)
- 7.5.2 Market Share by Region, 2025 & 2035 (%)
- 7.6 E-Commerce Pharmacies
- 7.6.1 Market Size by Region, 2025-2035 (US$ Million)
- 7.6.2 Market Share by Region, 2025 & 2035 (%)
- 8 Geographic Atrophy Market Analysis by Age Group
- 8.1 Key Findings
- 8.2 Age Group Segment: Market Attractiveness Index
- 8.3 Geographic Atrophy Market Size Estimation and Forecast by Age Group
- 8.4 Below 60 Years
- 8.4.1 Market Size by Region, 2025-2035 (US$ Million)
- 8.4.2 Market Share by Region, 2025 & 2035 (%)
- 8.5 Above 60 Years
- 8.5.1 Market Size by Region, 2025-2035 (US$ Million)
- 8.5.2 Market Share by Region, 2025 & 2035 (%)
- 8.6 Above 70 Years
- 8.6.1 Market Size by Region, 2025-2035 (US$ Million)
- 8.6.2 Market Share by Region, 2025 & 2035 (%)
- 9 Geographic Atrophy Market Analysis by Region
- 9.1 Key Findings
- 9.2 Regional Market Size Estimation and Forecast
- 10 North America Geographic Atrophy Market Analysis
- 10.1 Key Findings
- 10.2 North America Geographic Atrophy Market Attractiveness Index
- 10.3 North America Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
- 10.4 North America Geographic Atrophy Market Size Estimation and Forecast by Country
- 10.5 North America Geographic Atrophy Market Size Estimation and Forecast by Type
- 10.6 North America Geographic Atrophy Market Size Estimation and Forecast by Drugs
- 10.7 North America Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
- 10.8 North America Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
- 10.9 North America Geographic Atrophy Market Size Estimation and Forecast by Age Group
- 10.10 U.S. Geographic Atrophy Market Analysis
- 10.11 Canada Geographic Atrophy Market Analysis
- 11 Europe Geographic Atrophy Market Analysis
- 11.1 Key Findings
- 11.2 Europe Geographic Atrophy Market Attractiveness Index
- 11.3 Europe Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
- 11.4 Europe Geographic Atrophy Market Size Estimation and Forecast by Country
- 11.5 Europe Geographic Atrophy Market Size Estimation and Forecast by Type
- 11.6 Europe Geographic Atrophy Market Size Estimation and Forecast by Drugs
- 11.7 Europe Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
- 11.8 Europe Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
- 11.9 Europe Geographic Atrophy Market Size Estimation and Forecast by Age Group
- 11.10 Germany Geographic Atrophy Market Analysis
- 11.11 UK Geographic Atrophy Market Analysis
- 11.12 France Geographic Atrophy Market Analysis
- 11.13 Italy Geographic Atrophy Market Analysis
- 11.14 Spain Geographic Atrophy Market Analysis
- 11.15 Russia Geographic Atrophy Market Analysis
- 11.16 Netherlands Geographic Atrophy Market Analysis
- 11.17 Denmark Geographic Atrophy Market Analysis
- 11.18 Rest of Europe Geographic Atrophy Market Analysis
- 12 Asia Pacific Geographic Atrophy Market Analysis
- 12.1 Key Findings
- 12.2 Asia Pacific Geographic Atrophy Market Attractiveness Index
- 12.3 Asia Pacific Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
- 12.4 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Country
- 12.5 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Type
- 12.6 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Drugs
- 12.7 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
- 12.8 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
- 12.9 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Age Group
- 12.10 Japan Geographic Atrophy Market Analysis
- 12.11 China Geographic Atrophy Market Analysis
- 12.12 India Geographic Atrophy Market Analysis
- 12.13 Australia Geographic Atrophy Market Analysis
- 12.14 South Korea Geographic Atrophy Market Analysis
- 12.15 Rest of Asia Pacific Geographic Atrophy Market Analysis
- 13 Latin America Geographic Atrophy Market Analysis
- 13.1 Key Findings
- 13.2 Latin America Geographic Atrophy Market Attractiveness Index
- 13.3 Latin America Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
- 13.4 Latin America Geographic Atrophy Market Size Estimation and Forecast by Country
- 13.5 Latin America Geographic Atrophy Market Size Estimation and Forecast by Type
- 13.6 Latin America Geographic Atrophy Market Size Estimation and Forecast by Drugs
- 13.7 Latin America Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
- 13.8 Latin America Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
- 13.9 Latin America Geographic Atrophy Market Size Estimation and Forecast by Age Group
- 13.10 Brazil Geographic Atrophy Market Analysis
- 13.11 Mexico Geographic Atrophy Market Analysis
- 13.12 Rest of Latin America Geographic Atrophy Market Analysis
- 14 MEA Geographic Atrophy Market Analysis
- 14.1 Key Findings
- 14.2 MEA Geographic Atrophy Market Attractiveness Index
- 14.3 MEA Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
- 14.4 MEA Geographic Atrophy Market Size Estimation and Forecast by Country
- 14.5 MEA Geographic Atrophy Market Size Estimation and Forecast by Type
- 14.6 MEA Geographic Atrophy Market Size Estimation and Forecast by Drugs
- 14.7 MEA Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
- 14.8 MEA Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
- 14.9 MEA Geographic Atrophy Market Size Estimation and Forecast by Age Group
- 14.10 GCC Geographic Atrophy Market Analysis
- 14.11 South Africa Geographic Atrophy Market Analysis
- 14.12 Rest of MEA Geographic Atrophy Market Analysis
- 15 Company Profiles
- 15.1 Competitive Landscape, 2024
- 15.2 Strategic Outlook
- 15.1 Alkeus Pharmaceuticals, Inc.
- 15.1.1 Company Snapshot
- 15.1.2 Company Overview
- 15.1.3 Product Benchmarking
- 15.1.4 Strategic Outlook
- 15.1.5 SWOT Analysis
- 15.2 Bausch + Lomb
- 15.2.1 Company Snapshot
- 15.2.2 Company Overview
- 15.2.3 Financial Analysis
- 15.2.3.1 Net Revenue, 2020-2024
- 15.2.3.2 R&D, 2020-2024
- 15.2.3.3 Business Market Shares, 2024
- 15.2.4 Product Benchmarking
- 15.2.5 Strategic Outlook
- 15.2.6 SWOT Analysis
- 15.3 Ionis Pharmaceuticals
- 15.3.1 Company Snapshot
- 15.3.2 Company Overview
- 15.3.3 Financial Analysis
- 15.3.3.1 Net Revenue, 2020-2024
- 15.3.3.2 R&D, 2020-2024
- 15.3.3.3 Business Market Shares, 2024
- 15.3.4 Product Benchmarking
- 15.4 Santen Pharmaceutical Co., Ltd.
- 15.4.1 Company Snapshot
- 15.4.2 Company Overview
- 15.4.3 Financial Analysis
- 15.4.3.1 Net Revenue, 2020-2024
- 15.4.3.2 R&D, 2020-2024
- 15.4.4 Product Benchmarking
- 15.4.5 Strategic Outlook
- 15.5 Astellas Pharma Inc.
- 15.5.1 Company Snapshot
- 15.5.2 Company Overview
- 15.5.3 Financial Analysis
- 15.5.3.1 Net Revenue, 2020-2024
- 15.5.3.2 R&D, 2020-2024
- 15.5.3.3 Regional Market Shares, 2024
- 15.5.3.4 Business Market Shares, 2024
- 15.5.4 Product Benchmarking
- 15.5.5 Strategic Outlook
- 15.5.6 SWOT Analysis
- 15.6 Boehringer Ingelheim International GmbH
- 15.6.1 Company Snapshot
- 15.6.2 Company Overview
- 15.6.3 Financial Analysis
- 15.6.3.1 Net Revenue, 2020-2024
- 15.6.3.2 R&D, 2020-2024
- 15.6.3.3 Regional Market Shares, 2024
- 15.6.3.4 Business Market Shares, 2024
- 15.6.4 Product Benchmarking
- 15.6.5 Strategic Outlook
- 15.7 F. Hoffmann-La Roche Ltd.
- 15.7.1 Company Snapshot
- 15.7.2 Company Overview
- 15.7.3 Financial Analysis
- 15.7.3.1 Net Revenue, 2020-2024
- 15.7.3.2 R&D, 2020-2024
- 15.7.3.3 Business Market Shares, 2024
- 15.7.4 Product Benchmarking
- 15.7.5 Strategic Outlook
- 15.8 Apellis Pharmaceuticals
- 15.8.1 Company Snapshot
- 15.8.2 Company Overview
- 15.8.3 Financial Analysis
- 15.8.3.1 Net Revenue, 2020-2024
- 15.8.3.2 R&D, 2020-2024
- 15.8.3.3 Business Market Shares, 2024
- 15.8.4 Product Benchmarking
- 15.8.5 Strategic Outlook
- 15.8.6 SWOT Analysis
- 15.9 AstraZeneca
- 15.9.1 Company Snapshot
- 15.9.2 Company Overview
- 15.9.3 Financial Analysis
- 15.9.3.1 Net Revenue, 2020-2024
- 15.9.3.2 R&D, 2020-2024
- 15.9.3.3 Regional Market Shares, 2024
- 15.9.3.4 Business Market Shares, 2024
- 15.9.4 Product Benchmarking
- 15.9.5 Strategic Outlook
- 15.10 Johnson & Johnson
- 15.10.1 Company Snapshot
- 15.10.2 Company Overview
- 15.10.3 Financial Analysis
- 15.10.3.1 Net Revenue, 2020-2024
- 15.10.3.2 R&D, 2020-2024
- 15.10.3.3 Regional Market Shares, 2024
- 15.10.3.4 Business Market Shares, 2024
- 15.10.4 Product Benchmarking
- 15.11 Aviceda Therapeutics
- 15.11.1 Company Snapshot
- 15.11.2 Company Overview
- 15.11.3 Product Benchmarking
- 15.11.4 Strategic Outlook
- 15.12 Annexon, Inc.
- 15.12.1 Company Snapshot
- 15.12.2 Company Overview
- 15.12.3 Financial Analysis
- 15.12.3.1 R&D, 2020-2024
- 15.12.4 Product Benchmarking
- 15.12.5 Strategic Outlook
- 15.13 Stealth BioTherapeutics Inc.
- 15.13.1 Company Snapshot
- 15.13.2 Company Overview
- 15.13.3 Product Benchmarking
- 15.13.4 Strategic Outlook
- 15.14 Belite Bio‚Ñ¢ Inc.
- 15.14.1 Company Snapshot
- 15.14.2 Company Overview
- 15.14.3 Financial Analysis
- 15.14.3.1 R&D, 2020-2024
- 15.14.4 Product Benchmarking
- 15.14.5 Strategic Outlook
- 15.15 Cognition Therapeutics
- 15.15.1 Company Snapshot
- 15.15.2 Company Overview
- 15.15.3 Financial Analysis
- 15.15.3.1 R&D, 2020-2024
- 15.15.4 Product Benchmarking
- 15.15.5 Strategic Outlook
- 16 Conclusion and Recommendations
- 16.1 Concluding Remarks from Visiongain
- 16.2 Recommendations for Market Players
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
